Inventor · disambiguated record
Andrew Miksztal
Also filed as: MIKSZTAL ANDREW · MIKSZTAL ANDREW R
21 granted patents·15 pending applications·138 citations·filing 1994–2025
95Inventor score
Files withHELSINN HEALTHCARE SA16DURECT CORP9UNIV VIRGINIA COMMONWEALTH6SYNTEX INC2CALDERARI GIORGIO1
Top patents by PatentIndex Score
36 records- 0192US8598219B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2013·Granted Dec 3, 2013·6 cites·8 claims
- 0292US7960424B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2006·Granted Jun 14, 2011·16 cites·6 claims
- 0392US7947725B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2006·Granted May 24, 2011·15 cites·2 claims
- 0492US7947724B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2005·Granted May 24, 2011·16 cites·14 claims
- 0591US8729094B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2013·Granted May 20, 2014·5 cites·30 claims
- 0688US9125905B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2015·Granted Sep 8, 2015·2 cites·9 claims
- 0787US8598218B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2013·Granted Dec 3, 2013·6 cites·11 claims
- 0887US8518981B2Liquid pharmaceutical formulations of palonosetronCALDERARI GIORGIO·Filed 2011·Granted Aug 27, 2013·11 cites·12 claims
- 0986US9173942B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2013·Granted Nov 3, 2015·2 cites·19 claims
- 1084US11400019B2Sustained release drug delivery systems with reduced impurities and related methodsDURECT CORP·Filed 2021·Granted Aug 2, 2022·1 cites·27 claims
- 1183US9066980B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2013·Granted Jun 30, 2015·3 cites·16 claims
- 1279US11406646B2Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharideUNIV VIRGINIA COMMONWEALTH·Filed 2020·Granted Aug 9, 2022·1 cites·20 claims
- 1379US5543408ACrystalline anhydrous mycophenolate mofetil and intravenous formulation thereofSYNTEX INC·Filed 1994·Granted Aug 6, 1996·37 cites·12 claims
- 1478US12226423B2Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharideUNIV VIRGINIA COMMONWEALTH·Filed 2022·Granted Feb 18, 2025·0 cites·20 claims
- 1575US9308266B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2013·Granted Apr 12, 2016·1 cites·1 claims
- 1670US2024115463A1Sustained release drug delivery systems with reduced impurities and related methodsDURECT CORP·Filed 2023·Application pending·0 cites
- 1770US2018193262A1Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2017·Application pending·0 cites
- 1869US11771624B2Sustained release drug delivery systems with reduced impurities and related methodsDURECT CORP·Filed 2022·Granted Oct 3, 2023·0 cites·27 claims
- 1969US9457021B1Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2016·Granted Oct 4, 2016·0 cites·20 claims
- 2068US2017042807A1Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2016·Application pending·0 cites
- 2167US9439854B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2015·Granted Sep 13, 2016·0 cites·8 claims
- 2266US2025249021A1Compositions Comprising 5-Cholesten-3, 25-Diol, 3-Sulfate (25HC3S) or Pharmaceutically Acceptable Salt Thereof And at Least One Cyclic OligosaccharideUNIV VIRGINIA COMMONWEALTH·Filed 2025·Application pending·0 cites
- 2364US2014039000A1Liquid pharmaceutical formulations of palonosetronMACCIOCCHI SIMONE·Filed 2013·Application pending·0 cites
- 2463US2022175798A1Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglycerideDURECT CORP·Filed 2021·Application pending·0 cites
- 2562US9457020B2Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2015·Granted Oct 4, 2016·0 cites·3 claims
- 2662US2016317440A1Liquid pharmaceutical formulations of palonosetronHELSINN HEALTHCARE SA·Filed 2016·Application pending·0 cites
- 2760US5545637AProcess for preparing pharmaceutical compositions containing crystalline anhydrous mycophenolate mofetil saltsSYNTEX INC·Filed 1995·Granted Aug 13, 1996·16 cites·9 claims
- 2859US2021169902A1Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesionsUNIV VIRGINIA COMMONWEALTH·Filed 2020·Application pending·0 cites
- 2957US2024425545A125-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, SameDURECT CORP·Filed 2022·Application pending·0 cites
- 3055US2019374554A1Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesionsUNIV VIRGINIA COMMONWEALTH·Filed 2017·Application pending·0 cites
- 3153US2020222430A1Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglycerideDURECT CORP·Filed 2017·Application pending·0 cites
- 3252US2023365618A1Crystalline thiocholesterolDURECT CORP·Filed 2021·Application pending·0 cites
- 3351US12433877B2Sustained release drug delivery systems and related methodsDURECT CORP·Filed 2022·Granted Oct 7, 2025·0 cites·20 claims
- 3451US2019269695A1Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharideUNIV VIRGINIA COMMONWEALTH·Filed 2017·Application pending·0 cites
- 3550US2023056273A1Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing sameDURECT CORP·Filed 2020·Application pending·0 cites
- 3645US2004115236A1Devices and methods for management of inflammationFiled 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →